Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis) - PubMed
4 hours ago
- #Atopic Dermatitis
- #Abrocitinib
- #Real-world Study
- Abrocitinib is an oral Janus kinase 1 inhibitor used for moderate-to-severe atopic dermatitis (AD) in adults.
- Real-world study with 187 patients: mean age 37.9 years, 60.4% male, 50% bio-experienced, and 80% with difficult-to-treat areas.
- Efficacy improved over 52 weeks: IGA 0/1 increased from 52% at week 8 to 88% at week 52.
- EASI-90 response rose from 27.8% at week 8 to 79.6% at week 52, and itch response improved from 34.7% to 73.5%.
- Minimal disease activity increased from 18% at week 8 to 66% at week 52.
- Safety profile was good, with mild adverse events like abdominal pain, infections, and headache.
- 100 mg dose had similar efficacy to 200 mg but a better safety profile.